The world's first drug for the treatment of Ankylosing spondylitis has been introduced in Russia

A new domestic drug for the treatment of ankylosing spondylitis is successfully undergoing the third stage of clinical trials. At the same time, the drug was developed in Russia for about 19 years. This was reported on February 6 by RIA Novosti.

According to Sergey Lukyanov, rector of Pirogov University and one of the developers of the drug, the drug is based on a fundamentally new mechanism of action in the body. It selectively affects autoimmune lymphocytes, which play a major role in the development of the disease, without suppressing the immune system as a whole.

In addition, unlike most existing therapies, the drug does not have a general immunosuppressive effect. It is also noted that the drug is administered relatively rarely — once every six months or once a year. Such a regimen reduces the risk of addiction and loss of effectiveness with prolonged treatment.

Back in April 2024, the Ministry of Health of the Russian Federation announced the registration of the world's first drug for the treatment of Ankylosing spondylitis. It was noted that it showed high efficacy and safety according to the results of clinical trials. Later, the first batch of a medicinal product for the treatment of the disease entered into civil circulation in the territory of the Russian Federation. Also, studies of the drug have shown that the effect of its therapy begins from the first week of use and increases up to the 48th week.

All important news is on the Izvestia channel in the MAX messenger.